Trial Profile
A Randomized, Multicenter, Open Label, Phase 3 Study of Acalabrutinib (ACP-196) in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Alone in Subjects With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Rituximab (Primary) ; Ibrutinib
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Acerta Pharma
- 12 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Apr 2016 New trial record